Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | SDHB | P21912 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19262292 | 0.85 | RAD51 (0.42) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL19510145 | 0.82 | RAD51 (0.40) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL16804872 | 0.79 | RAD51 (0.47) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL15533905 | 0.76 | RAD51 (0.45) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL3561445 | 0.76 | ALDH1A1 (0.47) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL19262265 | 0.76 | RAD51 (0.45) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL16804876 | 0.76 | ADORA3 (0.53) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL3556359 | 0.76 | ADORA3 (0.50) | ADORA3RAD51MAPTNPC1RAB9A | |
| SCHEMBL4900477 | 0.75 | ADORA3 (0.56) | ADORA3PPARDMAPK1 | |
| SCHEMBL12539196 | 0.75 | KIF11 (0.43) | ADORA3TOP1LTA4HGSTO1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289508-A1 | NOVEL PYRIMIDINYL-DIAZOSPIRO COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10010551-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2018-07-03 | — | — | US | disclosed |
| US-10010551-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2018-07-03 | — | — | US | disclosed |
| US-20170304303-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170304303-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| US-9737536-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2017-08-22 | — | — | US | disclosed |
| US-9737536-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2017-08-22 | — | — | US | disclosed |
| EP-3106464-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160263115-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2016-09-15 | — | — | US | disclosed |
| US-20160263115-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2016-09-15 | — | — | US | disclosed |
| EP-2861602-B1 | 7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one | CONVERGENCE PHARMACEUTICALS (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-20160184306-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2016-06-30 | — | — | US | disclosed |
| US-9376445-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| US-9376445-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| US-9309254-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150166551-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166551-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150119404-A1 | NOVEL COMPOUNDS | CONVERGANCE PHARMACEUTICALS LIMITED (GB) | 2015-04-30 | — | — | US | disclosed |
| EP-2861594-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013175206-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184306-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | TRPV1, KCNJ2, KCNN2 | ADORA3 1428/4885RAD51 4602/4885MAPT 3413/4885 |
| US-20200289508-A1 | NOVEL PYRIMIDINYL-DIAZOSPIRO COMPOUNDS | TRPV1, KCNJ2, KCNN2 | ADORA3 1428/4885RAD51 4602/4885MAPT 3413/4885 |
| US-20150166551-A1 | NOVEL COMPOUNDS | KCNJ2, KCNN2, KCNN3 | ADORA3 2155/4885RAD51 4815/4885MAPT 2349/4885 |
| US-20160263115-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | TRPV1, KCNJ2, SCN1A | ADORA3 1622/4885RAD51 4520/4885MAPT 2731/4885 |
| US-10010551-B2 | Pyrimidinyl-diazospiro compounds | KCNJ2, TRPV1, SCN2A | ADORA3 1278/4885RAD51 4436/4885MAPT 3125/4885 |
| US-20170304303-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | TRPV1, KCNJ2, KCNN2 | ADORA3 1610/4885RAD51 4651/4885MAPT 3284/4885 |
| US-20150119404-A1 | NOVEL COMPOUNDS | KCNJ2, KCNN3, KCNN2 | ADORA3 1734/4885RAD51 4842/4885MAPT 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.